Free Newsletter
Who's afraid of the adverse event?
Can drug safety be scary? Apparently so. The FDA's new openness about potential safety problems appears to be scaring some patients off their medications, the Wall Street Journal reports. And according to a Pfizer survey, 89 percent of doctors worry that a deluge of warnings and cautions and "we're looking into this" announcements will prompt people to forego necessary treatment.
Granted, Pfizer has something of a vested interest in that outcome; its stop-smoking drug Chantix has garnered headlines every time the FDA mentioned its investigation into the drug's links with psychiatric side effects. (Indeed, the WSJ story mentions a woman who stopped taking the drug--without talking to her doctor--when she saw the media coverage.) But the FDA is taking the issue seriously, so much so that it plans to overhaul its "early communication" letters to include more info, in hopes of putting potential side effects in context.
- read the WSJ story
Related Articles:
Adverse event reports hit record high
Should FDA's info be in all DTC ads?
FDA issues more alerts--or does it?
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: